Innovative Therapeutics Profile
Key Indicators
- Authorised Capital ₹ 2.20 M
as on 22-06-2024
- Paid Up Capital ₹ 2.02 M
as on 22-06-2024
- Company Age 18 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 5.50 M
as on 22-06-2024
- Revenue 16.23%
(FY 2021)
- Profit 2.83%
(FY 2021)
- Ebitda 8.35%
(FY 2021)
- Net Worth 10.18%
(FY 2021)
- Total Assets 16.93%
(FY 2021)
About Innovative Therapeutics
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.20 M and a paid-up capital of Rs 2.02 M.
The company currently has active open charges totaling ₹5.50 M.
Saravanan Ellamanpettai and Sasirekha Chinnadurai serve as directors at the Company.
- CIN/LLPIN
U33112TN2006PTC060347
- Company No.
060347
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
26 Jun 2006
- Date of AGM
28 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Tiruvallur, Tamil Nadu, India
- Telephone
- Email Address
- Website
-
- Social Media
Who are the key members and board of directors at Innovative Therapeutics?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Saravanan Ellamanpettai  | Whole-Time Director | 26-Jun-2006 | Current |
| Sasirekha Chinnadurai | Director | 01-Oct-2008 | Current |
Financial Performance of Innovative Therapeutics.
Innovative Therapeutics Private Limited, for the financial year ended 2021, experienced significant growth in revenue, with a 16.23% increase. The company also saw a slight improvement in profitability, with a 2.83% increase in profit. The company's net worth Soared by an impressive increase of 10.18%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Innovative Therapeutics?
In 2021, Innovative Therapeutics had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Invocare Medtech Private LimitedActive 4 years 6 monthsSaravanan Ellamanpettai and Sasirekha Chinnadurai are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 21 Dec 2022 | ₹3.60 M | Open |
Indian Bank Creation Date: 04 Apr 2009 | ₹0.90 M | Open |
Indian Bank Creation Date: 25 Oct 2006 | ₹1.00 M | Open |
How Many Employees Work at Innovative Therapeutics?
Innovative Therapeutics has a workforce of 36 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Innovative Therapeutics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Innovative Therapeutics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
